Aptinyx's lead drug makes cut in small fibromyalgia trial, setting the stage for larger chronic pain study

Four months ago, its lead drug fell short of hitting statistical significance in a diabetic peripheral neuropathy (DPN) study. On Monday, the newly-public Aptinyx revealed the experimental treatment has scored in a small mid-stage fibromyalgia trial, paving the way for a larger study to begin in the second half of this year.